AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00073333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training
Description: Social skills training once per week
Study NCT00630695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide LP 90
Description: Lanreotide LP 90
Study NCT00630695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lanreotide
Description: Placebo
Study NCT03678389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESC
Description: USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
Study NCT06334276 — intervention group
Intervention type: OTHER
Intervention: Drowning
Description: Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid
Study NCT00273013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair
Description: Singulair will be available as over encapsulated 10 mg orange tablets.
Study NCT00273013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Singulair and GW274150 will be available.
Study NCT03400774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair-climbing
Description: Short bouts of moderate intensity stair-climbing
Study NCT03400774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stair-climbing
Description: Short bouts of moderate intensity stair-climbing
Study NCT03400774 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stair-climbing
Description: Short bouts of moderate intensity stair-climbing
Study NCT03818971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroretinogram (flash, pattern and multifocal)
Description: we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
Study NCT03818971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: electroretinogram (flash, pattern and multifocal)
Description: we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
Study NCT01788774 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone ISM 50 mg
Study NCT01788774 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone ISM 75 mg
Study NCT00073333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Treatment
Description: Exposure once per week
Study NCT00073333 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04005339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days
Study NCT04005339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
Study NCT04005339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 2,400 mg/m IV over 46 hours.
Study NCT01788774 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone ISM 100 mg
Study NCT06745141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: In the intervention group, patients underwent a comprehensive periodontal evaluation conducted by periodontists at a dental clinic. All permanent teeth, except for third molars, were assessed using dental mirrors and periodontal probes. Each tooth was examined at four sites (vestibular, distal, lingual, and mesial) to evaluate visible plaque, probing depth, probing bleeding, and attachment loss.~During the first treatment session, patients were provided with information about periodontal disease, emphasizing the importance of controlling supragingival bacterial biofilms for successful treatment. Plaque-retentive factors (calculus) were removed. Temporary materials were used to restore carious lesions, root remnants were extracted, and maladaptive restorations were adjusted. Supragingival calculus was removed using periodontal scalers, followed by cleaning with a rubber cup, prophylaxis paste, dental floss, and/or interdental brushes. No prophylactic antibiotics were used prior to the
Study NCT03737890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks.
Study NCT03737890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hold Relax Pectoral Stretch
Description: In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks.
Study NCT06745739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Training Workplace Prevention Program
Description: A workplace health promotion intervention for youth age 16-24, adapted from the school-based Life Skills Training program. The program teaches participants the skills necessary to be productive in work and personal settings while also promoting healthy behaviors and preventing or reducing health risk behaviors. Program content focuses on goal-setting and problem-solving skills, stress and anger management skills, effective communication and conflict management skills, time and financial management, substance use risk reduction, and how to contribute to a healthy, safe, and drug-free workplace.
Study NCT03465800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring
Description: self-monitoring of physical activity
Study NCT02733133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testagen® TDS Testosterone 5% HypoSpray®
Description: Topically applied Testosterone Hormone Replacement Lotion
Study NCT01525680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone augmented Prolonged Exposure Therapy
Description: 11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
Study NCT01525680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Prolonged exposure therapy with placebo administration
Description: 11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
Study NCT00377156 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiation therapy 5 days a week for 2.5 weeks
Study NCT00377156 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic radiosurgery
Study NCT00377156 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study NCT00452543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acamprosate
Description: Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
Study NCT00452543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study NCT00452543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: escitalopram
Description: Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
Study NCT00452543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical management
Description: Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
Study NCT00452543 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical management
Description: Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
Study NCT00452543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 capsules PO TID, for 12 weeks
Study NCT00686062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - computerized age-appropriate prenatal testing educational brochure
Description: Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
Study NCT00686062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT Tool - interactive, computerized, prenatal testing decision tool
Description: An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
Study NCT01584882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATI Tool
Description: Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
Study NCT02664350 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2D6
Description: Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
Study NCT02664350 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2D6
Description: Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
Study NCT02664350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory-Short Form (BPI-SF)
Description: This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
Study NCT02664350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pain Inventory-Short Form (BPI-SF)
Description: This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
Study NCT02664350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M.D. Anderson Symptom Inventory (MDASI)
Description: This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
Study NCT02664350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: M.D. Anderson Symptom Inventory (MDASI)
Description: This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
Study NCT02664350 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OPRM1
Description: Genetic testing of the OPRM1 will be performed after week 8.
Study NCT02664350 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: OPRM1
Description: Genetic testing of the OPRM1 will be performed after week 8.
Study NCT02397369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco users: Self Help
Description: This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
Study NCT02397369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco users:Telephonic counseling
Description: This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
Study NCT02397369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco users:Behavioural therapy Only
Description: 1. Focus Group discussion:~   This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.~2. Individual tobacco cessation counseling sessions:~Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant.
Study NCT02397369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco users:Pharmacologic
Description: Pharmaco Therapy will consist of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc
Study NCT01392066 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up.
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Study NCT01754740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uréia
Description: The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months.
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Study NCT01754740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
Study NCT04674319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: external cues and cogntive movement strategies
Description: external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section.
Study NCT04100603 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study NCT05143515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE label
Description: There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH
Study NCT02653092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Study NCT02653092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Euglycemic Clamp
Study NCT03465800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-monitoring
Description: self-monitoring of physical activity
Study NCT03465800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily incentives
Description: daily incentive payments for physical activity
Study NCT02071147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Clinical Follow up
Study NCT02071147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life questionnaire
Study NCT02071147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient satisfaction Questionnaire
Description: Conducted at Research clinic.
Study NCT04376177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.
Study NCT04376177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: angiography
Description: Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.
Study NCT04376177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaires
Description: Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.
Study NCT04376177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous oximetry
Description: Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.
Study NCT04376177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: plethysmography
Description: Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis
Study NCT04376177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyogram
Description: Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea
Study NCT04376177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard X-Ray
Description: Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
Study NCT02746367 — intervention group
Intervention type: OTHER
Intervention: Diagnostic test (LDT)
Description: Proteomic assay
Study NCT02092272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instructional exercise video source
Description: instructional exercise video source
Study NCT02452697 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NK Cell enriched-DLI only
Description: The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started.
Study NCT02452697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK-DLI + DUK-CPG-001
Description: DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI.